AGTC Expands Leadership Team with Appointment of Key Regulatory Leader
May 26, 2021 07:00 ET
|
Applied Genetic Technologies Corporation
AGTC Appoints Regulatory Expert, Janet C. Rae, RAC, as SVP of Global Regulatory and Quality GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies...
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021
May 17, 2021 16:05 ET
|
Applied Genetic Technologies Corporation
- Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria...
AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
May 13, 2021 16:03 ET
|
Applied Genetic Technologies Corporation
- Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an...
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 17, 2021
May 11, 2021 16:05 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...
AGTC Reports Process Development Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT
May 11, 2021 07:00 ET
|
Applied Genetic Technologies Corporation
-Improved process and validated expression assay support clinical phase product release for the Vista Phase 2/3 XLRP clinical trial- GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE...
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
May 06, 2021 07:00 ET
|
Applied Genetic Technologies Corporation
-Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials- -Best Corrected Visual Acuity (BCVA) data continue to provide supportive...
AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial
May 05, 2021 16:05 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...
AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
May 04, 2021 08:00 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...
AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials
May 03, 2021 08:39 ET
|
Applied Genetic Technologies Corporation
-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021- ALACHUA, Fla. and CAMBRIDGE, Mass., May 03, 2021 (GLOBE...
AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting
April 29, 2021 07:30 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...